S

SAB

Develops fully human polyclonal antibodies

Scientist: Analytical Development

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeSioux Falls, SD, USANo salary listed

About the Job

Requirements

  • A bachelor's degree in life sciences, biophysics, biochemistry, or a related discipline, plus 7 or more years of progressively responsible relevant experience in a biotech or pharmaceutical environment.
  • Hands-on expertise in A280, high-performance liquid chromatography, capillary electrophoresis sodium dodecyl sulfate, capillary isoelectric focusing, and liquid chromatography–mass spectrometry for biologics.
  • Experience with enzyme-linked immunosorbent assay and cell-based potency methods is a plus.
  • Strong understanding of method validation, method transfer, applicable guidelines including International Council for Harmonisation guidance, FDA guidance documents, USP/EP chapters, and current good manufacturing practice requirements.
  • Experience in reference standard programs, critical reagent programs, and forced degradation studies.
  • Ability to use established mathematical and scientific techniques, including simple statistical analysis, to compile and analyze data.
  • Proficiency in Microsoft Office applications, including Word, Excel, PowerPoint, and Outlook.
  • Ability to regularly move up to 10 pounds; close and peripheral vision and the ability to adjust focus; ability to view a computer monitor for extended periods.

Responsibilities

  • Lead and perform hands-on analytical work, including method development, qualification, validation, transfer to internal and external quality control laboratories, and lifecycle management; author method development, technical, qualification, and validation reports, as well as method standard operating procedures.
  • Ensure analytical readiness for late-stage development, process performance qualification, and commercial launch of the SAB-142 polyclonal antibody program.
  • Lead and perform method troubleshooting, optimization, bridging, and performance monitoring; conduct investigations into deviations, system suitability failures, out-of-trend and out-of-specification results; manage corrective and preventive actions, change control, and continuous method improvement; author associated documentation.
  • Contribute to qualification and stability monitoring of reference standards, assay controls, and critical reagents; qualify and test extended characterization assays; and conduct forced degradation and stress-sample studies.
  • Ensure internal and external partner analytical activities are scientifically rigorous and comply with current good manufacturing practice, International Council for Harmonisation guidance, United States Pharmacopeia, global regulations, quality by design principles, industry best practices, and company quality standards.
  • Contribute to specification setting and regulatory submissions.
  • Manage general laboratory operations and equipment qualification and maintenance; support scaling analytical capabilities, establishing a non-good-manufacturing-practice analytical development area, and implementing workflows and laboratory information management systems.
  • Partner with Quality Control and Quality Assurance to establish, maintain, and oversee analytical quality, good manufacturing practice compliance infrastructure, and inspection readiness for internal and external analytical documents and data.
  • Perform other duties and responsibilities as assigned.

Desired Qualifications

  • A master's degree is highly desirable.
  • Experience with enzyme-linked immunosorbent assay and cell-based potency methods is a plus.
  • Trend analysis and control charting experience is a plus.

About the Company

SAB

Develops fully human polyclonal antibodies

SAB Biotherapeutics creates fully human polyclonal antibody therapies using its DiversitAb platform, which uses genetically engineered transchromosomic cattle to produce human antibodies without needing donors. The antibodies are designed to address immunology disorders and infectious diseases, with programs like SAB-142 for Type 1 Diabetes, SAB-176 for severe influenza, and SAB-195 for C. diff. The platform enables faster development, potentially moving from concept to clinic in under five months. Unlike traditional monoclonal antibodies, SAB uses polyclonal human antibodies and works with governments and pharma partners to advance its pipeline toward approval and commercialization.

Company size
51-200
Company stage
IPO
Headquarters
Miami Beach, FL
Founded
2014

Recently Posted Jobs

Explore more opportunities at SAB

See more jobs